Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies - PubMed (original) (raw)

Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies

M Blank et al. Proc Natl Acad Sci U S A. 1991.

Abstract

The primary anti-phospholipid syndrome is characterized by recurrent venous and arterial thromboembolic phenomena, recurrent fetal loss, thrombocytopenia, and serological evidence of anti-cardiolipin (aCL) antibodies or/and the presence of lupus anticoagulant (prolonged activated partial thromboplastin time). The exact role of aCL antibodies in pathogenesis is not clear and the mechanism by which the antibodies may induce the various manifestations is unknown. In the current study we evaluated the effect of passive transfer of aCL antibodies (to the tail vein of naive mice) on fecundity, fetal loss (fetal resorption), and the weight of embryos and placentae. Two types of aCL antibodies were employed: (i) mouse monoclonal aCL antibodies derived from a BALB/c mouse in which experimental systemic lupus erythematosus was induced by a pathogenic idiotype (idiotype 16/6) of anti-DNA antibodies and (ii) polyclonal IgG and IgM aCL antibodies derived from serum of a patient with primary anti-phospholipid syndrome. After infusion of either antibody (10 micrograms per mouse) we could demonstrate lower fecundity rate, increased resorption index of embryos (equivalent to recurrent fetal loss), lower number of embryos per pregnancy, and lower mean weights of embryos and placentae in comparison to mice infused with appropriate control immunoglobulins. We conclude that the aCL antibodies may have direct effects on fecundity and on the outcome of pregnancy.

PubMed Disclaimer

Similar articles

• Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice.
  Piona A, La Rosa L, Tincani A, Faden D, Magro G, Grasso S, Nicoletti F, Balestrieri G, Meroni PL. Piona A, et al. Scand J Immunol. 1995 May;41(5):427-32. doi: 10.1111/j.1365-3083.1995.tb03588.x. Scand J Immunol. 1995. PMID: 7725061
• Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype.
  Blank M, Krause I, Ben-Bassat M, Shoenfeld Y. Blank M, et al. J Autoimmun. 1992 Aug;5(4):495-509. doi: 10.1016/0896-8411(92)90008-e. J Autoimmun. 1992. PMID: 1418290
• Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3).
  Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Bakimer R, et al. J Clin Invest. 1992 May;89(5):1558-63. doi: 10.1172/JCI115749. J Clin Invest. 1992. PMID: 1569194 Free PMC article.
• The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
  Arnout J. Arnout J. Verh K Acad Geneeskd Belg. 2000;62(5):353-72. Verh K Acad Geneeskd Belg. 2000. PMID: 11144685 Review.
• Antiphospholipid antibodies--autoantibodies with a difference.
  Harris EN, Asherson RA, Hughes GR. Harris EN, et al. Annu Rev Med. 1988;39:261-71. doi: 10.1146/annurev.me.39.020188.001401. Annu Rev Med. 1988. PMID: 3130772 Review.

Cited by

• Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.
  Bernardi M, Spadafora L, Andaloro S, Piscitelli A, Fornaci G, Intonti C, Fratta AE, Hsu CE, Kaziròd-Wolski K, Metsovitis T, Biondi-Zoccai G, Sabouret P, Marzetti E, Cacciatore S. Bernardi M, et al. J Clin Med. 2024 May 23;13(11):3064. doi: 10.3390/jcm13113064. J Clin Med. 2024. PMID: 38892776 Free PMC article. Review.
• The pathogenesis of obstetric APS: a 2023 update.
  Mineo C, Shaul PW, Bermas BL. Mineo C, et al. Clin Immunol. 2023 Oct;255:109745. doi: 10.1016/j.clim.2023.109745. Epub 2023 Aug 23. Clin Immunol. 2023. PMID: 37625670 Free PMC article. Review.
• Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.
  Knight JS, Kanthi Y. Knight JS, et al. Semin Immunopathol. 2022 May;44(3):347-362. doi: 10.1007/s00281-022-00916-w. Epub 2022 Feb 4. Semin Immunopathol. 2022. PMID: 35122116 Free PMC article. Review.
• Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy.
  Lee EE, Jun JK, Lee EB. Lee EE, et al. J Korean Med Sci. 2021 Jan 25;36(4):e24. doi: 10.3346/jkms.2021.36.e24. J Korean Med Sci. 2021. PMID: 33496084 Free PMC article. Review.
• Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository.
  Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, Fortin PR, Ji L, Efthymiou M, Cohen H, Branch DW, de Jesus GR, Andreoli L, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhaiya M; APS ACTION Investigators. Sevim E, et al. Arthritis Care Res (Hoboken). 2022 Feb;74(2):324-335. doi: 10.1002/acr.24468. Arthritis Care Res (Hoboken). 2022. PMID: 32986935 Free PMC article.

References

1. 1. Ann Intern Med. 1986 Feb;104(2):175-80 - PubMed
2. 1. Ann Rheum Dis. 1989 Oct;48(10):795-7 - PubMed
3. 1. Clin Immunol Immunopathol. 1986 Oct;41(1):8-15 - PubMed
4. 1. Br J Rheumatol. 1987 Oct;26(5):346-50 - PubMed
5. 1. Klin Wochenschr. 1987 Sep 15;65(18):852-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information